Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer
Authors
Keywords
-
Journal
Expert Review of Gastroenterology & Hepatology
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2021-02-16
DOI
10.1080/17474124.2021.1890031
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In Regard to “A Phase Ib Study of NUC ‐1031 in Combination with Cisplatin for the First‐Line Treatment of Patients with Advanced Biliary Tract Cancer ( ABC ‐08)”
- (2021) Angela Dalia Ricci et al. ONCOLOGIST
- PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
- (2021) Alessandro Rizzo et al. Cancers
- Systemic therapies for intrahepatic cholangiocarcinoma
- (2020) Robin Kate Kelley et al. JOURNAL OF HEPATOLOGY
- Adjuvant chemotherapy in biliary tract cancer
- (2020) Dilara Akhoundova Sanoyan et al. CURRENT OPINION IN ONCOLOGY
- Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
- (2020) Angela Lamarca et al. JOURNAL OF HEPATOLOGY
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
- (2020) ALESSANDRO RIZZO et al. ANTICANCER RESEARCH
- Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials
- (2020) A. Belkouz et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- New Treatment Options for Advanced Biliary Tract Cancer
- (2020) Jonathan D. Mizrahi et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- Regarding “ HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer”
- (2020) Alessandro Rizzo et al. ONCOLOGIST
- Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine
- (2020) Ines Malenica et al. Cancers
- Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis
- (2020) Francesco Massari et al. Expert Opinion On Drug Safety
- Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
- (2020) Angela Dalia Ricci et al. Cancer Control
- Evolution of the Experimental Models of Cholangiocarcinoma
- (2020) Annamaria Massa et al. Cancers
- The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
- (2020) Angela Dalia Ricci et al. ESMO Open
- Combination therapy of dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer
- (2020) Alessandro Rizzo et al. Hepatobiliary & Pancreatic Diseases International
- BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care
- (2020) Alessandro Rizzo et al. Expert Review of Gastroenterology & Hepatology
- Recent advances of immunotherapy for biliary tract cancer
- (2020) Alessandro Rizzo et al. Expert Review of Gastroenterology & Hepatology
- A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs)
- (2020) Shuting Han et al. Cancers
- Clinical presentation, diagnosis and staging of cholangiocarcinoma
- (2019) Alejandro Forner et al. LIVER INTERNATIONAL
- Adjuvant capecitabine in biliary tract cancer: a standard option?
- (2019) David Malka et al. LANCET ONCOLOGY
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
- (2019) John N Primrose et al. LANCET ONCOLOGY
- Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
- (2019) Rachna T. Shroff et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
- (2019) Julien Edeline et al. JOURNAL OF CLINICAL ONCOLOGY
- Current status of the adjuvant therapy in uterine sarcoma: A literature review
- (2019) Alessandro Rizzo et al. World Journal of Clinical Cases
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- Current standards and future perspectives in adjuvant treatment for biliary tract cancers
- (2019) Angela Lamarca et al. CANCER TREATMENT REVIEWS
- Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
- (2019) Alessandro Rizzo et al. Future Oncology
- Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
- (2018) T. Ebata et al. BRITISH JOURNAL OF SURGERY
- Adjuvant Therapy for Biliary Tract Cancers: New Evidence to Resolve Old Questions
- (2018) Jordan M. Cloyd et al. Journal of Oncology Practice
- The impact of perioperative CA19-9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma
- (2017) Byoung Hyuck Kim et al. JOURNAL OF SURGICAL ONCOLOGY
- Risk estimation for biliary tract cancer: Development and validation of a prognostic score
- (2017) Nora Schweitzer et al. LIVER INTERNATIONAL
- Cholangiocarcinoma — evolving concepts and therapeutic strategies
- (2017) Sumera Rizvi et al. Nature Reviews Clinical Oncology
- Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update
- (2017) Aarti Sharma et al. WORLD JOURNAL OF GASTROENTEROLOGY
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) J. W. Valle et al. ANNALS OF ONCOLOGY
- Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
- (2016) Faiz Gani et al. ANNALS OF SURGICAL ONCOLOGY
- Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management
- (2016) Han Zhang et al. CANCER LETTERS
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
- (2016) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
- (2016) Supriya K. Saha et al. ONCOLOGIST
- SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
- (2015) Edgar Ben-Josef et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
- (2013) Sumera Rizvi et al. GASTROENTEROLOGY
- Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy
- (2013) Yizhou Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma
- (2012) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
- (2012) Anne M. Horgan et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors
- (2012) Yoshiaki Murakami et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) F. Eckel et al. ANNALS OF ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant therapy for resected extrahepatic cholangiocarcinoma: A review of the literature and future directions
- (2009) Carryn Anderson et al. CANCER TREATMENT REVIEWS
- Gemcitabine-Based Adjuvant Chemotherapy Improves Survival After Aggressive Surgery for Hilar Cholangiocarcinoma
- (2009) Yoshiaki Murakami et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Surgical Management and Prognostic Factors of Hilar Cholangiocarcinoma: Experience with 115 Cases in China
- (2008) Liu Yubin et al. ANNALS OF SURGICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now